

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8110832

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
HERMANN KURT RUSS	03/10/2016
MICHAL GEVA	03/09/2016
RALPH LAUFER	02/08/2017
ARIC ORBACH	02/08/2017
RECEIVING PARTY DATA	
Name:	TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Street Address:	SCHLÜSSELSTRASSE 12
City:	JONA
State/Country:	SWITZERLAND
Postal Code:	8645
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16078929
CORRESPONDENCE DATA	
Fax Number:	(646)878-0801
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	646-878-0800
Email:	USPTO@PearlCohen.com
Correspondent Name:	PEARL COHEN ZEDEK LATZER BARATZ LLP
Address Line 1:	7 TIMES SQUARE, 19TH FLOOR
Address Line 4:	NEW YORK, NEW YORK 10036
ATTORNEY DOCKET NUMBER:	P-584530-US
NAME OF SUBMITTER:	TANYA MICHAELI
SIGNATURE:	/TM/
DATE SIGNED:	08/13/2023
Total Attachments: 8	
source=P-584530-US-SIGNED-ASSIGNMENT-INV-to-TEVA#page1.tif	
source=P-584530-US-SIGNED-ASSIGNMENT-INV-to-TEVA#page2.tif	
source=P-584530-US-SIGNED-ASSIGNMENT-INV-to-TEVA#page3.tif	

source=P-584530-US-SIGNED-ASSIGNMENT-INV-to-TEVA#page4.tif

source=P-584530-US-SIGNED-ASSIGNMENT-INV-to-TEVA#page5.tif

source=P-584530-US-SIGNED-ASSIGNMENT-INV-to-TEVA#page6.tif

source=P-584530-US-SIGNED-ASSIGNMENT-INV-to-TEVA#page7.tif

source=P-584530-US-SIGNED-ASSIGNMENT-INV-to-TEVA#page8.tif

PATENT

REEL: 064573 FRAME: 0320

Attorney Docket No. 88421-PRO//PW/GIG/ITC

ASSIGNMENT OF PROVISIONAL APPLICATION

In consideration of One Dollar (\$1.00), and other good and valuable considerations, the receipt of which is hereby acknowledged, we, the undersigned,

Hermann Kurt Russ, of Zürcherstrasse 37c, Altendorf, Switzerland 8852; and

Michal Geva, of Rozmarin 5, P.O. Box 7253, Even-Yehuda, Israel

effective February 24, 2016

Hereby sell, assign and transfer to Teva Pharmaceuticals International GmbH, a corporation of Switzerland, having a place of business at Schlüsselstrasse 12, 8645 Jona, Switzerland, its successors, assigns and legal representatives, the entire right, title and interest for all countries, in and to any and all inventions which are disclosed in the provisional application for United States Patent, which is entitled

TREATMENT OF NEURODEGENERATIVE EYE DISEASE USING PRIDOPIDINE

(United States Provisional Application No. 62/299,290, filed February 24, 2016)

and in and to said application and all non-provisional applications for United States Patent, including divisional, continuing, substitute, renewal, and reissue thereof, and all other applications for U.S. Letters Patent or other related property rights in any and all foreign countries which have been or shall be filed on any of said inventions disclosed in said provisional application; and in and to all original and reissued patents or related foreign documents which have been or shall be issued on said inventions;


Authorize and request the Commissioner for Patents of the United States to

issue to said Assignee, the corporation above named, its successors, assigns and legal representatives, in accordance with this assignment, any and all United States Letters Patent on said inventions or any of them disclosed in said application;


Agree that said Assignee may apply for and receive foreign Letters Patent or rights of any other kind for said inventions, or any of them; and may claim, in applications for said foreign Letters Patent or other rights, the priority of the aforesaid United States provisional patent application under the provisions of the International Convention of 1883 and later modifications thereof, under the Patent Cooperation Treaty, under the European Patent Convention or under any other available international agreement; and that, when requested, without charge to, but at the expense of, said Assignee, its successors, assigns and legal representatives, to carry out in good faith the intent and purpose of this assignment, the undersigned or the undersigned's executors or administrators will, for the United States and all foreign countries, execute all nonprovisional applications for United States Patent, including any divisional, continuing, substitute, renewal, and reissue thereof, and all other patent applications or other documents on any and all said inventions; execute all rightful oaths, assignments, powers of attorney and other papers; communicate to said Assignee, its successors, assigns and representatives, all facts known and documents available to the undersigned relating to said inventions and the history thereof; testify in all legal proceedings; and generally do everything possible which said Assignee, its successors, assigns or representatives shall consider desirable for aiding in securing, maintaining and enforcing proper patent protection for said inventions and for vesting title to said inventions and all applications for patents or related foreign rights and all patents on said inventions, in said Assignee, its successors, assigns and legal representatives; and

Covenant with said Assignee, its successors, assigns and legal representatives that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by the undersigned,

and that full right to convey the same as herein expressed is possessed by the undersigned.

 [LS]
Hermann Kurt Russ

Date: March 10, 2016
Witness: Jiliana Eichholzer [signature]
Jiliana Eichholzer [printed name]
Brunnenzelestr. 1 [address]
8904 Aesch
Switzerland

Date: 3/9/2016
Witness:  [signature]
JOEL KAYE [printed name]
228 DUCHIFFE ST [address]
NATANYA, 42571 ISRAEL

Attorney Docket No. 88421-PRO//PW/GJG//TC

ASSIGNMENT OF PROVISIONAL APPLICATION

In consideration of One Dollar (\$1.00), and other good and valuable considerations, the receipt of which is hereby acknowledged, we, the undersigned,

Ralph Laufer, of Shenkin 55, Tel Aviv 6523309, Israel; and

Aric Orbach, Levona 1, Rehovot 76350, Israel;

effective February 24, 2016

Hereby sell, assign and transfer to Teva Pharmaceuticals International GmbH, a corporation of Switzerland, having a place of business at Schlüsselstrasse 12, 8645 Jona, Switzerland, its successors, assigns and legal representatives, the entire right, title and interest for all countries, in and to any and all inventions which are disclosed in the provisional application for United States Patent, which is entitled

TREATMENT OF NEURODEGENERATIVE EYE DISEASE USING PRIDOPIDINE

(United States Provisional Application No. 62/299,290 , filed February 24, 2016)

and in and to said application and all non-provisional applications for United States Patent, including divisional, continuing, substitute, renewal, and reissue thereof, and all other applications for U.S. Letters Patent or other related property rights in any and all foreign countries which have been or shall be filed on any of said inventions disclosed in said provisional application; and in and to all original and reissued patents or related foreign documents which have been or shall be issued on said inventions;

Authorize and request the Commissioner for Patents of the United States to

issue to said Assignee, the corporation above named, its successors, assigns and legal representatives, in accordance with this assignment, any and all United States Letters Patent on said inventions or any of them disclosed in said application;

Agree that said Assignee may apply for and receive foreign Letters Patent or rights of any other kind for said inventions, or any of them; and may claim, in applications for said foreign Letters Patent or other rights, the priority of the aforesaid United States provisional patent application under the provisions of the International Convention of 1883 and later modifications thereof, under the Patent Cooperation Treaty, under the European Patent Convention or under any other available international agreement; and that, when requested, without charge to, but at the expense of, said Assignee, its successors, assigns and legal representatives, to carry out in good faith the intent and purpose of this assignment, the undersigned or the undersigned's executors or administrators will, for the United States and all foreign countries, execute all nonprovisional applications for United States Patent, including any divisional, continuing, substitute, renewal, and reissue thereof, and all other patent applications or other documents on any and all said inventions; execute all rightful oaths, assignments, powers of attorney and other papers; communicate to said Assignee, its successors, assigns and representatives, all facts known and documents available to the undersigned relating to said inventions and the history thereof; testify in all legal proceedings; and generally do everything possible which said Assignee, its successors, assigns or representatives shall consider desirable for aiding in securing, maintaining and enforcing proper patent protection for said inventions and for vesting title to said inventions and all applications for patents or related foreign rights and all patents on said inventions, in said Assignee, its successors, assigns and legal representatives; and

Covenant with said Assignee, its successors, assigns and legal representatives that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by the undersigned, and that full right to convey the same as herein expressed is possessed by the undersigned.

Date: Feb 1
 Witness: Atalyah Samuel [signature]
Atalyah Samuel [printed name]
Hachera [address]

[Signature] [LS]
 Ralph Laufer

Date: _____
 Witness: _____ [signature]
 _____ [printed name]
 _____ [address]

 Aric Orbach [LS]

Teva Pharmaceuticals International GmbH hereby accepts the assignment of rights set forth above.

By: _____ [LS.]
 Printed Name:
 Title:
 Date:
 Witness:
 _____ [signature]
 _____ [printed name]
 _____ [address]

By: _____ [LS.]
 Printed Name:
 Title:
 Date:
 Witness:
 _____ [signature]
 _____ [printed name]
 _____ [address]

Date: _____ [LS]
 Witness: _____ [signature]
 _____ [printed name]
 _____ [address]

Ralph Laufer

Date: Feb 8, 2017
 Witness: _____ [signature]
 NATALIE HARARI [printed name]
 22 HANERMON ST [address]
 ALFEI MENASHE

_____ [LS]
 Aric Orbach

Teva Pharmaceuticals International GmbH hereby accepts the assignment of rights set forth above.

By: _____ [LS.]	By: _____ [LS.]
Printed Name:	Printed Name:
Title:	Title:
Date:	Date:
Witness:	Witness:
_____ [signature]	_____ [signature]
_____ [printed name]	_____ [printed name]
_____ [address]	_____ [address]
_____	_____

_____ [LS]
 Date: _____ Ralph Laufer
 Witness: _____ [signature]
 _____ [printed name]
 _____ [address]

_____ [LS]
 Date: _____ Aric Orbach
 Witness: _____ [signature]
 _____ [printed name]
 _____ [address]

Teva Pharmaceuticals International GmbH hereby accepts the assignment of rights set forth above.

By: [Signature] [LS.]
 Printed Name: David Koch
 Title: President of the Managing Officers
 Date: 27 January 2017
 Witness: [Signature] [signature]
SILVANA BALLETO [printed name]
c/o PLUS CHEMICALS [address]
Via San Salvatore 7
6902 LUOGNO-PARADISO

By: [Signature] [LS.]
 Printed Name: Naama Baran
 Title: General Manager
 Date: 1.2.2017
 Witness: [Signature] [signature]
GARINER TRACCHI [printed name]
SCHLOSSECKENASSE 12 [address]
8045 - JONA